France Archives

News and Trends 16 Dec 2014

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers. An initial partnership agreement was concluded in 2013 and the results of work on the 3C23K antibody were presented to the Ovarian […]

December 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 6 Dec 2014

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro […]

December 6, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

Deinocossus Synthetic biology france leading

News and Trends 18 Nov 2014

Is France Leading the European Synthetic Biology-Based Biofuel Field?

France has great Synthetic Biology Biotech companies. Paris-based Global Bioenergies carried out the first isobutene production trial in its industrial pilot of Pomacle-Bazancourt in the east of France. Two other companies, Deinove and Fermentalg are growing extremely fast, and giant Total is investing massively in the field. Is France on the good way to become […]

November 18, 2014 - 3 minutesmins - By Julie Lellouche

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year. It is a huge step forward in treating type 2 diabetes. Indeed, most people forget […]

November 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Oct 2014

Review : Ebola, The True Story

The first outbreaks of Ebola (also known as Ebola haemorrhagic fever) have occurred in isolated villages in central Africa, near tropical forests, but the recent outbreak in West Africa has affected major urban centers as well as rural areas. The Ebola virus disease shows an average fatality rate about 50%. In previous outbreaks, the rate […]

October 30, 2014 - 26 minutesmins - By Cédric Brock

News and Trends 29 Oct 2014

Sanofi Fires its CEO Chris Viehbacher

Breaking news for French Pharma company Sanofi. The Board decided to fire Christopher Viehbacher, who was leading the company since December 2008. Chris Viehbacher, German-Canadian, was the first non-French CEO of Sanofi, second largest French company. He had a tough management and tried to transform Sanofi (maybe too much). He managed Sanofi’s transition to Biotech/Biologicals with […]

October 29, 2014 - 2 minutesmins - By Philip Hemme

News and Trends 28 Oct 2014

Stem Cell Therapy for Degenerative Muscle Disease thanks to ENDOSTEM Project

ENDOSTEM project aims to identify an agent capable of ‘boosting’ stem cells already present in muscle tissue for a more efficient tissue repair to tackle degenerative muscle disease. Muscular dystrophy is a type of degenerative muscle disease. One of its most known forms, Duchenne muscular dystrophy, affects 1 over 3 500 boys worldwide. It affects patients progressively, they […]

October 28, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2014

The First French Biotech entered successfully on the NASDAQ

DBV Technologies entered on the NASDAQ last Wednesday raising up to 90 million euros. It bets on treating peanut allergy, which is a major health issue in the United States, and targets up to one billion dollars revenues. The small French biotechnology company which has developed a new system of allergy desensitization based on skin patches launched […]

October 23, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 10 Oct 2014

How Gilead’s Hepatitis C Treatment challenges European Public Health Systems

American Biotech company Gilead is selling its new drug Sovaldi since 2013, which brings significant breakthrough in Hepatitis C treatment. The high cost of the drug, up to €100 000, is a challenge for european Public Health system which tries to lower its overall cost for their public health system. Hepatitis C is an infectious disease […]

October 10, 2014 - 3 minutesmins - By Philip Hemme

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

France

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Will there be a New Merck-Serono?

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

New Technologies Against Allergies are on the Wave

Is France Leading the European Synthetic Biology-Based Biofuel Field?

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Review : Ebola, The True Story

Sanofi Fires its CEO Chris Viehbacher

Stem Cell Therapy for Degenerative Muscle Disease thanks to ENDOSTEM Project

The First French Biotech entered successfully on the NASDAQ

How Gilead’s Hepatitis C Treatment challenges European Public Health Systems

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!